10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Phospho-CBL (S669) Antibody
Rabbit mAb
Catalog # AP92850

Specification

Phospho-CBL (S669) Antibody - Product Information

Application	**WB**
Primary Accession	P22681
Reactivity	**Rat**
Clonality	**Monoclonal**

Other Names
Casitas B lineage lymphoma proto oncogene; cbl; CBL2; E3 ubiquitin protein ligase CBL; Oncogene CBL2; Proto oncogene c CBL; RING finger protein 55; RNF55; Signal transduction protein CBL;

Isotype	**Rabbit IgG**
Host	**Rabbit**
Calculated MW	**99633 Da**

Phospho-CBL (S669) Antibody - Additional Information

Dilution	**WB~~1:1000**
Purification	**Affinity-chromatography**
Immunogen	**A synthesized peptide derived from human Phospho-CBL (S669)**
Description	**Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome.**
Storage Condition and Buffer	**Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.**

Phospho-CBL (S669) Antibody - Protein Information

Name CBL

Synonyms CBL2, RNF55

Function
E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:<a

href="http://www.uniprot.org/citations/10514377" target="_blank">10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:10514377, PubMed:14661060, PubMed:14739300, PubMed:17094949, PubMed:17509076, PubMed:17974561). Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signaling (PubMed:15190072, PubMed:18374639, PubMed:21596750). Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation (PubMed:11896602). Ubiquitinates EGFR and SPRY2 (PubMed:17094949, PubMed:17974561). Ubiquitinates NECTIN1 following association between NECTIN1 and herpes simplex virus 1/HHV-1 envelope glycoprotein D, leading to NECTIN1 removal from cell surface (PubMed:28381567). Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis (PubMed:15190072, PubMed:18374639). Essential for osteoclastic bone resorption (PubMed:14739300). The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function (PubMed:14739300). May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity).

Cellular Location
Cytoplasm. Cell membrane. Cell projection, cilium. Golgi apparatus. Note=Colocalizes with FGFR2 in lipid rafts at the cell membrane

Phospho-CBL (S669) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Phospho-CBL (S669) Antibody - Images



Western blot analysis of Phospho-CBL (S669) expression in (1) HeLa cell lysate; (2) HeLa cell treated with pervanadate lysate.